Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Describe the efficacy of the use of topical besifloxacin in reducing the conjunctival microbiota as a prophylactic measure in patients scheduled for cataract surgery.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana
• Treatments: Besifloxacin; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Subjects over 18 years of age scheduled for cataract surgery in the established study period.

• Subjects physically and mentally capable of applying the eye drops or having a person available to help in the correct administration of the eye drops 4 times a day.

Exclusion Criteria:

• - Active eye infection (bacterial, viral, fungal or parasitic) such as blepharitis and / or conjunctivitis.

• Known allergy or any contraindication to the use of quinolones or any of the components of the drugs.